Corvus prices IPO at $15, the low end of the range

Corvus Pharmaceuticals, which is developing checkpoint inhibitors to treat solid tumors, raised $71 million by offering 4.7 million shares at $15, the low end of the range of $15 to $17. 

Corvus Pharmaceuticals plans to list on the Nasdaq under the symbol CRVS. Credit Suisse and Cowen & Company acted as lead managers on the deal.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.